Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
24.90
-0.09 (-0.36%)
Official Closing Price
Updated: 7:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
99
100
Next >
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
September 27, 2025
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and...
Via
MarketMinute
Topics
Economy
Intellectual Property
Abbott India Limited: A Deep Dive into its Robust Forecast and Valuation Outlook Amidst a Thriving Indian Pharma Market
September 27, 2025
Mumbai, India – September 27, 2025 – Abbott India Limited (NSE: ABBOTINDIA), a prominent player in the Indian pharmaceutical sector, is exhibiting a robust financial trajectory and a promising...
Via
MarketMinute
Topics
Economy
Intellectual Property
US Government Braces for Unprecedented Shutdown: Economic Fallout Looms as Deadline Nears
September 27, 2025
As the clock ticks towards midnight on September 30, 2025, the United States government stands on the precipice of a highly imminent and seemingly unavoidable shutdown. With just days left until the...
Via
MarketMinute
Topics
Economy
Government
Workforce
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
↗
September 27, 2025
The company continues to improve its pipeline.
Via
The Motley Fool
3 Magnificent Stocks Under $100 to Buy Right Now
↗
September 27, 2025
You won't need a huge amount of cash to invest in these great pharma stocks.
Via
The Motley Fool
Pfizer is Locking in New Growth Through a New Acquisition
↗
September 26, 2025
Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet.
Via
MarketBeat
Topics
Artificial Intelligence
Pfizer Faces Court Over Depo-Provera Brain Tumor Claims
↗
September 26, 2025
Pfizer Inc.
Via
Benzinga
Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst
↗
September 26, 2025
President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly...
Via
Benzinga
Topics
Government
World Trade
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?
↗
September 26, 2025
The pharmaceutical giant is again plunging headfirst into weight-loss drug development.
Via
The Motley Fool
Topics
Intellectual Property
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
↗
September 26, 2025
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de
Via
Benzinga
Topics
Government
World Trade
2 Top Passive Income Stocks to Buy Now
↗
September 26, 2025
These dividend stocks offer high yields and growth catalysts that could support payouts for decades.
Via
The Motley Fool
Topics
Bonds
Economy
Lawsuit
3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now
↗
September 26, 2025
These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.
Via
The Motley Fool
Topics
World Trade
2 Oversold Stocks Primed to Rebound and 1 Facing Challenges
September 26, 2025
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...
Via
StockStory
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'
↗
September 26, 2025
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.
Via
Benzinga
Hearing Against Pfizer Set For 29 September In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio
September 25, 2025
From
Levin Papantonio
Via
Business Wire
Most active S&P500 stocks in Thursday's session
↗
September 25, 2025
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via
Chartmill
Does This Acquisition Make Pfizer Stock a Great Buy?
↗
September 25, 2025
There's an opportunity to get in on the weight-loss drug craze at a reasonable price.
Via
The Motley Fool
Topics
Death
Intellectual Property
Pfizer Tries To Fatten Its Profits With Weight Loss Drugs
↗
September 25, 2025
Pfizer needs to fortify its future revenues.
Via
Talk Markets
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
September 25, 2025
From
Pfizer Inc.
Via
Business Wire
3 Top Dividend Stocks to Buy and Hold Forever
↗
September 25, 2025
These blue chip dividend stocks offer both income and growth potential.
Via
The Motley Fool
Topics
Intellectual Property
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.
↗
September 25, 2025
Investors once speculated that Pfizer might consider acquiring Viking.
Via
The Motley Fool
Healthcare Sector Grapples with 5% Slump in 2025: A Deep Dive into Market Underperformance
September 24, 2025
The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
What's Driving the Market Sentiment Around Pfizer?
↗
September 24, 2025
Via
Benzinga
Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High
↗
September 24, 2025
The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months.
Via
Investor's Business Daily
Topics
Intellectual Property
The Smartest Dividend Stock to Buy With $1,000 Right Now
↗
September 24, 2025
Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.
Via
The Motley Fool
Topics
Intellectual Property
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
↗
September 24, 2025
Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.
Via
The Motley Fool
Topics
Intellectual Property
Where Will Pfizer Be in 5 Years?
↗
September 24, 2025
The pharma giant may be heading for a new era of growth.
Via
The Motley Fool
Topics
Intellectual Property
Time To Buy Pfizer Or Metsera Stock?
↗
September 24, 2025
Making a major move in the obesity drug market, Pfizer announced on Monday that it plans to acquire biotechnology firm Metsera by the end of the year for $4.9 billion or $47.50 a share.
Via
Talk Markets
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
September 23, 2025
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights...
Via
MarketMinute
Topics
Intellectual Property
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
September 23, 2025
From
Pfizer Inc.
Via
Business Wire
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.